Pre-made Ubamatamab benchmark antibody ( Whole mAb, anti-MUC16;CD3E therapeutic antibody, Anti-CA125;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Ubamatamab (formerly REGN 4018), a human bispecific antibody targeted against MUC16 (on tumour cells) and CD3 (on T cells), is being developed by Regeneron Pharmaceuticals for the treatment of ovarian cancer, fallopian tube cancer and peritoneal cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-705-1mg	1mg	Inquiry
GMP-Bios-ab-705-10mg	10mg	Inquiry
GMP-Bios-ab-705-100mg	100mg	Inquiry
GMP-Bios-ab-705-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Ubamatamab
Target	MUC16;CD3E
Format	Bispecific Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4;IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2021
Year Recommended	na
Companies	Regeneron Pharmaceuticals
Conditions Approved	na
Conditions Active	Fallopian tube cancer;Ovarian cancer;Peritoneal cancer
Conditions Discontinued	na
Development Tech	na